SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 7,868.02 |
| Enterprise Value ($M) | 8,057.35 |
| Book Value ($M) | 2,018.03 |
| Book Value / Share | 12.77 |
| Price / Book | 3.90 |
| NCAV ($M) | 1.01 |
| NCAV / Share | 0.01 |
| Price / NCAV | 7,821.10 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.05 |
| Return on Assets (ROA) | 0.05 |
| Return on Equity (ROE) | 0.07 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.58 |
| Current Ratio | 3.71 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 627.24 |
| Assets | 2,644.26 |
| Liabilities | 626.23 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Price T Rowe Associates Inc /md/ | 5.90 | ||
| 13G/A | BlackRock, Inc. | 8.70 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 797,807 | 3,639,143 | 21.92 | |
| 976,887 | 3,126,334 | 31.25 | |
| 522,499 | 2,432,257 | 21.48 | |
| 471,602 | 1,469,756 | 32.09 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SWTX – SpringWorks Therapeutics, Inc. | SYRE – Spyre Therapeutics, Inc. |
| TARS – Tarsus Pharmaceuticals, Inc. | TERN – Terns Pharmaceuticals, Inc. |
| TLRY – Tilray Brands, Inc. |
Financial data and stock pages provided by
Fintel.io